ST. JOSEPH, Mich., April 14 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Professor Marcelo Bento Soares of Children's Memorial Research Center has joined the MetaMiner Stem Cell Partnership Program. The goal of the program is to develop a series of blueprint pathway maps for adult, embryonic, fetal, fibroblasts, hematopoietic, mesenchymal, multipotent, neoplastic, pluripotent and totipotent stem cells.
"We feel that it is important to support such an initiative as there is a lot of stem cell information in the literature but no one has brought it all together in a set of comprehensive pathway maps," said Professor Marcelo Bento Soares, Director, Cancer Biology and Epigenomics Program. "This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly."
"We had our kick off meeting last month and it went very well; we have a lot of other companies and academic groups that want to join this important project as this will be the first stem cell pathway platform for researchers to advance science. Stem cell research is attracting a lot of attention at the moment," said Julie Bryant, GeneGo's VP of Business Development. "We have a lot of experience in building pathway maps and we plan to have 10 types of stem cell drug centric pathway maps completed in 24 months."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.
For more information, please visit the company's web site at www.genego.com.
About Children's Memorial Research Center
The mission of Children's Memorial Research Center is to generate new knowledge leading to advancements in the prevention, diagnosis, and treatment of diseases that affect the development of children through adolescence as well as adult disorders that derive from them. Our multidisciplinary teams of physicians, scientists, technicians, nurses and trainees are committed to making discoveries that will improve the lives of children and their families.
|SOURCE GeneGo, Inc.|
Copyright©2009 PR Newswire.
All rights reserved